Resectable Pancreatic Adenocarcinoma Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Resectable Pancreatic Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled454 locationsNCT04858334
Recruiting
Phase 1

TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmStage III Pancreatic Cancer AJCC v8+5 more
University of California, Davis52 enrolled1 locationNCT07189195
Recruiting
Phase 1

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma+1 more
PanTher Therapeutics26 enrolled6 locationsNCT06673017
Recruiting
Phase 3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma+2 more
SWOG Cancer Research Network94 enrolled196 locationsNCT06998940
Recruiting
Phase 1Phase 2

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Borderline Resectable Pancreatic AdenocarcinomaResectable Pancreatic AdenocarcinomaLocalized Pancreatic Adenocarcinoma
Amsterdam UMC, location VUmc66 enrolled4 locationsNCT06384560
Recruiting
Phase 2

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

Borderline Resectable Pancreatic Adenocarcinoma
Zhejiang University40 enrolled2 locationsNCT07240766
Recruiting
Phase 2

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+3 more
Mayo Clinic25 enrolled1 locationNCT06381154
Recruiting

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

Stage IV Lung Cancer AJCC v8Unresectable Lung Non-Small Cell CarcinomaStage IV Pancreatic Cancer AJCC v8+6 more
University of Rochester800 enrolled225 locationsNCT06073431
Recruiting

Identify microRNAs in Cachexia in Pancreatic Carcinoma

Resectable Pancreatic Adenocarcinoma
University of Oklahoma100 enrolled1 locationNCT05275075
Recruiting
Phase 1

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma+1 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04484909
Recruiting
Phase 2

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Resectable Pancreatic Adenocarcinoma+2 more
Emory University36 enrolled1 locationNCT06423326
Recruiting

A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

Borderline Resectable Pancreatic AdenocarcinomaResectable Pancreatic Adenocarcinoma
Ruijin Hospital119 enrolled2 locationsNCT07080021
Recruiting
Not Applicable

Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

Pancreatic CancerAdenocarcinomaResectable Pancreatic Adenocarcinoma+3 more
University Hospital, Clermont-Ferrand100 enrolled1 locationNCT06649474
Recruiting
Phase 3

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Pancreatic CancerPancreatic Ductal AdenocarcinomaResectable Pancreatic Adenocarcinoma
Erasmus Medical Center378 enrolled22 locationsNCT04927780
Recruiting
Phase 2

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Pancreatic AdenocarcinomaPancreatic NeoplasmBorderline Resectable Pancreatic Adenocarcinoma
Erasme University Hospital256 enrolled10 locationsNCT05083247
Recruiting

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

SurgeryQuality of LifePancreas Cancer+6 more
Umeå University300 enrolled1 locationNCT05356039